[Changes of plasminogen activator inhibitor-1 and D-dimer during continuous blood purification and related factors].
OBJECTIVE
To observe the changes of plasminogen activator inhibitor-1 and D-dimer during continuous blood purification (CBP) and related factors.


METHODS
Sixteen patients who were diagnosed with multiple organ dysfunction syndrome (MODS) were randomly divided into 2 groups: 8 patients received standard continuous blood purification with heparin anticoagulation, and the other 8 received CBP without anticoagulation. Ten normal blood samples were collected from healthy volunteers as controls. All patients underwent CBP for 8 h. Blood was taken from those patients at 0, 15, 60, 120 and 480 min during the CBP. Plasma plasminogen activator inhibitor-1, D-dimer and serum TNF-α and IL-1β were measured by ELISA.


RESULTS
Plasma levels of PAI-1 and D-dimer were increased significantly compared with those in the control group (P<0.05). Plasma level of PAI-1 was reduced (P<0.05) and D-dimer was increased (P<0.05) after the CBP. The level of plasma PAI-1 in the heparin group was significant reduced compared with the group of CBP without anticoagulation (P<0.05). There was negative correlation between the level of PAI-1 and the dosage of heparin used during a CBP session in the heparin group (r=-0.746, P<0.001).


CONCLUSIONS
The level of PAI-1 and D-dimer is higher in patients with MODS than that in the normal controls. After the CBP treatment, there is significant decrease in PAI-1 and increase in D-dimer in both groups. Heparin used during CBP can reduce PAI-1 which intensifies its function of anticoagulation.
Department of Nephrology, Third XianYa Hospital, Changsha 410013, China.
Jianwen
J
Wang
Youming
Y
Peng
Hao
H
Zhang
Bin
B
Yi
Ke
K
Zhang
Jun
J
Liu
Jishi
J
Liu
D000925:Anticoagulants / Q000627:therapeutic use; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D006435:Renal Dialysis; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D053583:Interleukin-1beta; D017395:Plasminogen Activator Inhibitor 1; D014409:Tumor Necrosis Factor-alpha; C036309:fibrin fragment D; D006493:Heparin